Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Imitrex Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
June 25, 2007
Shire’s Intuniv™ for ADHD: Old Drug, Same Use
Analysis of: Shire Receives Approvable Letter from FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD | www.pipelinereview.com
Author: GLG Expert Contributor
Stimulants remain by far the first line of treatment for ADHD.  However, these drugs have a high incidence of abuse liability.  There is a great need to develop effective but non-stimulant treatments for ADHD.
May 23, 2007
PCR Used to Detect Bad Meat
Analysis of: New Test May Allow For Rapid Detection Of Salmonella In Meat | www.medicalnewstoday.com
Author: GLG Expert Contributor
PCR analysis of meat for Salmonella was compared to traditional culture methods The PCR technique showed a relatively high sensitivity and specificity for the organism much more rapidly
April 24, 2007
EPIX Pharmaceutical Goes After Serotonin Receptor Type 6
Analysis of: EPIX Pharmaceuticals Announces Statistically Signficant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate | www.pipelinereview.com
Author: GLG Expert Contributor
Serotonin 5-HT6 receptor remains one of the obscure serotonin receptor subtypes that need further evaluation to better understand its physiological and neurochemical roles.  The recent development of selective 5-HT6 receptor agonists and antagonists is paving the way to achieve this goal.
April 19, 2007
Antidepressants in Adolescents: To Use or Not to Use
Analysis of: Antidepressants Get a Boost For Use in Teens | online.wsj.com
Author: GLG Expert Contributor
Based on meta-analysis of 24 trials, FDA issued a Black Box warning against use of antidepressants in children and adolescents due to a 2-fold increase in suicidal thoughts and behavior in pediatric patients.  The use of antidepressants for the treatment of major depressive disorders in the pediatric...
April 16, 2007
NeuroSearch’s ACR16: The Many Faces of a New “Dopamine Stabilizer”
Analysis of: NeuroSearch's license partner Astellas initiates clinical Phase Ib study with ACR16 in patients with schizophrenia | www.pipelinereview.com
Author: GLG Expert Contributor
Although the market for antipsychotic drugs is becoming more crowded, it remains a big market and there is always room for a new drug that would provide therapeutic or safety advantages over current treatments.
April 16, 2007
Watch Out TV: Here Comes the Internet!!
Analysis of: J&J is Wired About the Web | www.pharmexec.com
Author: GLG Expert Contributor
Pharmaceutical companies are always exploring new avenues to communicate with a broader base of consumers.  However, marketing budgets have ballooned to unprecedented levels, and they are placing heavy burdens on these companies. Any effective cost-cutting measure would be a welcomed step.
April 13, 2007
Lower Dose of Risperidal® Consta®: Will it Make a Difference?!
Analysis of: FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment | biz.yahoo.com
Author: GLG Expert Contributor
Patients’ compliance remains a problematic issue in treatment of schizophrenia patients.  Antipsychotic drugs that can be given once every 2 or 4 weeks may provide a pharmacotherapeutic alternative to daily treatment with oral antipsychotic agents.
April 11, 2007
Lilly’s Strattera® for ADHD: Non-Stimulant but Non-Effective
Analysis of: Study Shows Children With ADHD Who Start on Strattera(R) are More Likely to Change Therapies | www.drugnewswire.com
Author: GLG Expert Contributor
Strattera®, developed by Eli Lilly & Co. (NYSE: LLY), is the first FDA-approved non-stimulant, non-scheduled drug for treatment of ADHD.  It was thought that Strattera® would provide an alternative to the widely used stimulant medications for ADHD children.  However, the drug...
April 11, 2007
Xenoport: Banking on XP13512 for RLS and Neuropathic Pain
Analysis of: GlaxoSmithKline and XenoPort announce agreement on late-stage compound for RLS and neuropathic pain | www.pipelinereview.com
Author: GLG Expert Contributor
Restless Leg syndrome (RLS) a neurological disorder characterized by an uncontrollable urge to move the legs. Patients describe feelings of burning, creeping, or tugging inside the legs.  Requip® is the only FDA-approved drug for the treatment of moderate to severe RLS.  
April 5, 2007
Allon Therapeutics: New Approach for treatment of cognitive deficits in schizophrenia
Analysis of: Allon receives approval to begin a Phase II clinical trial for Schizophrenia | www.pipelinereview.com
Author: GLG Expert Contributor
There is a great need to develop novel agents that exhibit new mechanisms of action to further improve cognitive deficits and negative symptoms in patients with schizophrenia.

Previous Page : 1 2 3 4 5 6 7 Next31 to 40 of 67

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747